10-K: Microbot Medical Inc. Reports Full Year 2023 Results and Provides Business Update

Microbot Medical Inc. released its 2023 annual report, detailing financial results and progress on its LIBERTY robotic surgical system.

Summary

• Microbot Medical Inc. reported its financial results for the year ended December 31, 2023, showing a net loss of $10.74 million.
• The company's research and development expenses decreased to $5.72 million in 2023 from $7.74 million in 2022, primarily due to cost reduction measures.
• General and administrative expenses also decreased to $4.13 million in 2023 from $5.55 million in 2022.
• The company had cash, cash equivalents, and marketable securities of approximately $6.4 million as of December 31, 2023.
• Microbot is focused on the development of its LIBERTY Endovascular Robotic Surgical System and has submitted an IDE application to the FDA to commence human clinical trials.
• The company is also working towards CE Mark approval for the LIBERTY system in Europe.
• Microbot has ceased research and development activities for other platforms, including SCS and TipCat, to focus on the LIBERTY system.
• The company settled a lawsuit for $2.15 million, consisting of cash and shares of common stock.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is progress in product development and regulatory submissions, the company's financial situation is concerning, with significant losses and a going concern warning. The ongoing war in Israel and supply chain issues add to the uncertainty.

Positives

• The company has made significant progress in the development of the LIBERTY Endovascular Robotic Surgical System, including successful preclinical studies and an IDE submission.
• Microbot has taken steps to reduce operating costs, which has resulted in lower research and development and general and administrative expenses.
• The company is actively pursuing regulatory approvals in both the U.S. and Europe.
• Microbot has successfully raised additional capital through equity offerings and warrant exercises.
• The company has resolved a significant legal issue through a settlement agreement.

Negatives

• Microbot has incurred significant operating losses since its inception and expects to continue to incur losses for the foreseeable future.
• The company has a limited operating history outside of being a research and development-stage company.
• There is substantial doubt regarding the company's ability to continue as a going concern.
• Microbot is dependent on the success of its sole lead product candidate, the LIBERTY Endovascular Robotic Surgical System.
• The company has terminated its agreement with CardioSert and returned the related technology.
• The company is experiencing delays in the supply of certain components from Israeli-based vendors due to the Israel-Hamas war.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital.
• Unsuccessful animal studies or clinical trials could have a material adverse effect on the company's prospects.
• The company may not meet its development and commercialization objectives in a timely manner or at all.
• Microbot's ability to expand its technology platforms for other uses may be limited.
• The company's technology acquired from CardioSert is subject to a buy-back clause which was triggered.
• The company is dependent on third-party manufacturers and suppliers.
• The company may be subject to penalties and may be precluded from marketing its product candidates if it fails to comply with extensive governmental regulations.
• The company's operations in Israel are subject to political and military risks.
• The company may be subject to intellectual property litigation and infringement claims.
• The company's stock price may be volatile.

Future Outlook

The company expects to continue to incur losses for the foreseeable future as it continues the development of, and seeks regulatory review of, its product candidates, and begins to commercialize any approved or cleared products following a successful regulatory review. The company intends to continue to opportunistically strengthen its balance sheet by raising additional funds through equity offerings, including possibly through its existing but currently suspended At-the-Market offering, or otherwise in order to meet expected future liquidity needs, including the introduction of the LIBERTY Endovascular Robotic Surgical System.

Management Comments

• Management believes the company has sufficient funds for its operations for less than one year.
• Management believes that the company's third-party vendors and service providers have their own respective cybersecurity protocols which our management believes to be adequate for protecting any of the Company's data that might be in their possession from time to time.

Industry Context

The document highlights the growing market for minimally invasive surgery and the potential for robotic systems in endovascular interventions. The company positions its LIBERTY system as a solution to the limitations of current manual procedures and existing robotic systems, emphasizing its compact, disposable, and remotely controlled design.

Comparison to Industry Standards

• The document mentions Corindus Vascular Robotics (Siemens Healthineers) and Robocath as competitors in the endovascular robotics space.
• Microbot believes its LIBERTY system has advantages over these competitors, such as greater maneuverability, disposability, and lower capital expenditure requirements.
• The document also notes that the U.S. market growth in endoluminal robotic surgery is projected to be 15-25% by 2025, indicating a strong growth potential for the company's products.
• The company is aiming to establish the LIBERTY system as the standard of care in the eyes of medical practitioners, patients and medical facilities, as well as getting the support of payors and insurance companies.

Corporate Governance

Legal Proceedings

• The company settled a lawsuit for $2.154 million, consisting of $1.1 million in cash and 1,005,965 shares of restricted common stock.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity offerings and potential loss of investment due to the company's financial challenges.
• Employees may be affected by potential cost-cutting measures or changes in the company's direction.
• Customers and partners may be impacted by delays in product development or commercialization.
• Suppliers may be affected by the company's financial instability and potential changes in its operations.

Next Steps

• Continue interaction with the FDA regarding the IDE submission process.
• Commence audits for ISO 13485 certification to ensure compliance with EU Medical Devices Regulation.
• Continue to seek new sources of capital to stabilize finances and provide operating runway.
• Continue to work with the subcontractor to transfer the production to the subcontractor.

Key Dates

Keywords

robotic surgery, endovascular, LIBERTY system, medical device, clinical trials, FDA, CE Mark, preclinical study, regulatory approval, capital raise